Semaglutide for prevention or cure of HFpEF?
The results of the STEP-HFpEF trial point towards routine use of GLP-1 agonists in heart failure but this has to be balanced against conflicting guidelines and cost pressures… read more.
The results of the STEP-HFpEF trial point towards routine use of GLP-1 agonists in heart failure but this has to be balanced against conflicting guidelines and cost pressures… read more.
The results of the STEP-HFpEF trial showed statistically significant benefits “across the board” and these benefits were not due to weight loss alone, according to Vicky Ruszala, Specialist… read more.
STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with… read more.
Tirzepatide. a once weekly GIP and GLP-1 receptor agonist, treats early-onset type 2 diabetes as effectively as it treats type 2 diabetes diagnosed later in life, researchers reported… read more.
Your weekly digest of the top healthcare stories, covering news published from 02/10/2023 – 06/10/2023. Daily Express Eating disorders more than doubled among young people during the pandemic,… read more.
Data from a “real world” study indicates that treatment with the semaglutide (Ozempic/Wegovy) for type 2 diabetes significantly improves both blood sugar control and weight loss for up… read more.
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents… read more.
In the future, GLP-1 agonists could be used early in treatment for type II diabetes and this could have an important impact on slowing the onset of complications,… read more.
GLP-1 agonists such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents are now… read more.
There has been a recent three-fold increase in obesity-related deaths from heart disease in the U.S. between 1999 and 2020, according to new research published today in the Journal of… read more.
A new opinion piece published in Health Affairs Forefront raises questions around current approaches to assess drug safety and effectiveness in people with obesity. The article sheds light on how… read more.
Your weekly digest of the top healthcare stories, covering news published from 21/08/2023 – 25/08/2023. The Guardian Women with chronic fatigue syndrome (CFS) tend to have more symptoms… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.